Private Equity & Portfolio Operations
Technology diligence that survives the close.
Where the cost shows up
Technology diligence is compressed into a window that rewards speed over depth, and the integration cost that was not surfaced before close becomes an operating problem afterwards. EXOS works with operating partners and portfolio operations teams on the technology assessment, the post-close estate, and the value creation plan that has to be evidenced at exit.
Evidence
Healthlink Advisors is the clearest case and the only publicly verifiable one. A 60+ person KLAS-ranked healthcare IT advisory firm used institutional knowledge assetization to demonstrate acquisition-ready value; in October 2025 a larger healthcare consultancy of 1,450+ professionals acquired it. Advisory methodology became a measurable organizational asset rather than a dependency on individual partners — which is directly a valuation argument. Linked from the case library.
Common questions
Why does institutional knowledge affect valuation?
Because a firm whose capability is resident in a few individuals carries key-person risk a buyer will price. Where methodology has been captured as a transferable organizational asset, the acquirer is buying something that survives the earn-out.
Can EXOS support technology diligence inside a deal timeline?
Technology and application estate assessment is core EXOS work. Deal timelines compress it, and the honest constraint is that compressed diligence surfaces less. Where prior engagement patterns are retained, later assessments start from accumulated judgment rather than a blank page.